10-Q: SRx Health Solutions Faces Steep Losses, Canadian Unit Files for Creditor Protection

SRx Health Solutions Inc. reported a significant increase in net loss and a 65% drop in net sales for the nine months ended June 30, 2025, with its Canadian subsidiary filing for creditor protection post-period end.

Summary

• Net sales decreased by 65% to $41.1 million for the nine months ended June 30, 2025, from $117.1 million in the prior year.
• Gross profit declined by 56% to $10.3 million for the nine months ended June 30, 2025, compared to $23.4 million in the same period last year.
• Operating loss widened to $32.2 million for the nine months ended June 30, 2025, from $8.2 million in the previous year.
• Net loss increased by 169% to $29.7 million for the nine months ended June 30, 2025, compared to $11.1 million in the prior year.
• Adjusted EBITDA worsened significantly to a loss of $19.1 million for the nine months ended June 30, 2025, from a loss of $0.135 million in the prior year.
• The company reported a working capital deficiency of $49.6 million as of June 30, 2025, an improvement from $67.7 million as of September 30, 2024.
• SRx Canada, the company's primary operating subsidiary, commenced proceedings under the Companies Creditors Arrangement Act (Canada) (CCAA) on August 11, 2025, due to liquidity constraints.
• A reverse merger with Better Choice Company, Inc. was consummated on April 24, 2025, with SRx Canada identified as the accounting acquirer, resulting in a preliminary bargain purchase gain of $1.69 million.
• The company was not in compliance with financial covenants on its senior secured term facilities with Canadian Western Bank (CWB) as of June 30, 2025, leading to the classification of the entire $23.1 million CWB loan as a current liability.
• Material weaknesses in internal control over financial reporting were identified for the fiscal year ended September 30, 2024, including issues with documentation, fair value determinations, debt agreement signatures, management override of controls, and IT general controls.
• The company raised $8.8 million in a private placement on April 24, 2025, by issuing common stock and pre-funded warrants.
• Subsequent to June 30, 2025, the company secured an Equity Line of Credit for up to $50 million and issued $7.65 million in senior secured convertible notes and warrants.
• Approximately 18.8 million shares were forfeited and cancelled on August 1, 2025, through a Settlement, Share Forfeiture and Mutual Release Agreement.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, evidenced by substantial losses, declining revenue, negative Adjusted EBITDA, and a going concern warning. The CCAA filing for its core Canadian operations and identified material weaknesses in internal controls highlight significant operational and governance challenges. While recent capital raises and asset disposals offer some liquidity, the overall outlook is highly uncertain and negative.

Positives

• Working capital deficiency improved to $49.6 million as of June 30, 2025, from $67.7 million as of September 30, 2024.
• Cash and cash equivalents increased to $0.912 million as of June 30, 2025, from $0.106 million as of September 30, 2024.
• The reverse merger with Better Choice Company, Inc. resulted in a preliminary bargain purchase gain of $1.69 million.
• The company generated a net gain of $4.3 million from the disposal of assets during the nine months ended June 30, 2025, through the sale of several pharmacy locations and a warehouse building.
• Secured an Equity Line of Credit for up to $50 million and $7.65 million in senior secured convertible notes and warrants post-period end, providing potential future liquidity.
• The share cancellation settlement agreement on August 1, 2025, resulted in the forfeiture and cancellation of approximately 18.8 million shares, reducing the fully diluted share count.

Negatives

• Net sales decreased by 65% to $41.1 million for the nine months ended June 30, 2025, primarily due to liquidity constraints limiting the ability to purchase and dispense high-cost specialty medications.
• Net loss significantly increased by 169% to $29.7 million for the nine months ended June 30, 2025, compared to $11.1 million in the prior year.
• Operating loss worsened by 292% to $32.2 million for the nine months ended June 30, 2025.
• Adjusted EBITDA showed a substantial loss of $19.1 million for the nine months ended June 30, 2025, compared to a loss of $0.135 million in the prior year.
• The company is not in compliance with financial covenants on its $23.1 million senior secured term facilities with Canadian Western Bank (CWB), leading to the debt being classified as current and callable by the lender.
• SRx Canada, the core Canadian operating subsidiary, filed for creditor protection under the CCAA on August 11, 2025, indicating severe financial distress.
• Material weaknesses in internal control over financial reporting were identified, including management override of controls by the former CFO redirecting RRSP contributions to fund operations without appropriate approval.
• The U.S. pet food business (Halo) continues to experience significant liquidity constraints and operating losses, remaining reliant on external financing.
• Impairment expense of $2.69 million was recognized for customer list intangible assets during the nine months ended June 30, 2025.
• Goodwill impairment charge of $19.7 million was recognized for the fiscal year ended September 30, 2024, due to loss of a key contract and challenging industry dynamics.
• Professional fees increased by 285% to $5.2 million for the nine months ended June 30, 2025, largely due to reverse merger transaction expenses.
• A prepaid consulting agreement of $8.6 million with Terra Nova Business Holdings Inc. was written off subsequent to June 30, 2025, following the CCAA filing.

Risks

• Ability to continue as a going concern due to recurring operating losses, negative operating cash flows, working capital deficiency, and covenant violations.
• Impact of damage to or interruption of information technology systems due to cyber-attacks or other circumstances beyond control.
• Business interruptions resulting from geopolitical actions, including war and terrorism.
• Failure to successfully implement growth strategy or manage anticipated growth.
• Inability to achieve or maintain profitability.
• Loss of key members of the senior management team.
• Inability to generate sufficient cash flow or raise capital on acceptable terms to run operations, service debt, and make necessary capital expenditures.
• Dependence on subsidiaries for payments, advances, and transfers of funds due to holding company status.
• Inability to successfully develop additional products and services or successfully market and commercialize such products and services.
• Intense competition in the market.
• Inability to attract new and retain existing customers, suppliers, distributors, or retail partners.
• Allegations that products cause injury or illness or fail to comply with government regulations.
• Inability to manage the supply chain effectively.
• Inability of the company or its co-manufacturers and suppliers to comply with legal and regulatory requirements.
• Effect of potential price increases and shortages on inputs, commodities, and ingredients due to broader geopolitical and macroeconomic conditions.
• Inability to develop and maintain brand and brand reputation.
• Compliance with data privacy rules.
• Inflationary pressures.
• Compliance with applicable regulations issued by the U.S. Food and Drug Administration (FDA), the U.S. Federal Trade Commission (FTC), the U.S. Department of Agriculture (USDA), and other federal, state, and local regulatory authorities.
• Risk of product recalls for a variety of reasons, including product defects, packaging safety, and inadequate or inaccurate labeling disclosure.
• Risk of shifting customer demand in relation to raw pet foods, premium kibble, and canned pet food products, and failure to respond to such changes in customer taste quickly and effectively.
• Uncertain outcome of the CCAA process, with no assurance that the company will be successful in implementing a viable restructuring plan.
• Significant liquidity constraints and operating losses in the U.S. pet food business, which remains reliant on external financing.
• Potential adverse effects from significant changes in legislation, regulation, government policy, and economic conditions, including international trade policy and tariffs.
• Litigation and other proceedings that arise in the ordinary course of business, with unpredictable outcomes.

Future Outlook

The company aims to expand its leadership in Canada's specialty healthcare landscape, driven by increasing demand for specialty medications and health system capacity challenges. Management is actively pursuing plans to address going concern uncertainties, including seeking additional capital, restructuring debt, implementing cost controls, scaling higher-margin service lines, expanding commercial footprint, and evaluating divestiture of non-core assets. The U.S. pet food business is under evaluation for strategic alternatives, including restructuring, divestiture, or wind-down.

Management Comments

• "At SRx, we make specialty healthcare simple for Canadians."
• "Our mission is to simplify access to complex therapies and improve health outcomes for patients with chronic, rare, or specialty conditions."
• "We believe that increasing demand for specialty medications, alongside health system capacity challenges, will continue to drive strong tailwinds for our model."
• "SRx is well-positioned to expand our leadership role in Canadas specialty healthcare landscape."
• "Management is committed to strengthening the Companys internal control environment and is in the process of evaluating potential enhancements to address the significant deficiencies identified during the most recent audit."

Industry Context

The company operates in the Canadian specialty healthcare market, which is experiencing increasing demand for high-cost, high-complexity therapies for chronic, rare, or specialty diseases. This trend, coupled with health system capacity challenges, creates a favorable environment for integrated healthcare providers like SRx. However, the U.S. pet food market, where its Halo brand operates, faces significant liquidity constraints and operating losses, suggesting a more challenging competitive or demand environment for that segment. The company's strategy to divest non-core assets and focus on higher-margin services aligns with a broader industry trend of specialization and efficiency in healthcare.

Management Changes

Corporate Governance

Legal Proceedings

• The company may be involved in legal proceedings, claims, and regulatory, tax, or government inquiries and investigations that arise in the ordinary course of business.
• Management is not aware of any claims or lawsuits that may have a material adverse effect on the condensed consolidated financial position or results of operations of the company.

Related Party Transactions

• Historical non-interest-bearing working capital advances with the largest shareholder and entities under common control were forgiven, and the company recorded a capital contribution.
• A $1.4 million balance due to Adesh Vora, the company's former Chief Executive Officer, transitioned into a payable position during the pre-merger period in the three months ended June 30, 2025, recorded as an increase to beginning accumulated deficit and a non-cash capital distribution.
• No other related party loans or receivables were outstanding for any shareholder with greater than 10% ownership as of June 30, 2025, and September 30, 2024.
• The company does not intend to enter into similar related party lending arrangements in the future.

Stakeholder Impact

• Shareholders face significant dilution risk from ongoing capital raises and share issuances, including the Equity Line of Credit and convertible notes. Share forfeiture and cancellation agreement reduced outstanding shares, but overall value is impacted by severe financial distress and CCAA filing.
• Creditors, particularly Canadian Western Bank, face increased risk of default as debt is classified as current and callable due to covenant non-compliance. The CCAA filing for SRx Canada impacts their ability to recover.
• Employees may be affected by workforce reductions and efforts to streamline the cost structure as part of the CCAA process, indicating potential job losses.
• Customers in the Health Solutions segment may experience impacts on service delivery and patient volumes due to operational disruptions and staffing/service reductions caused by liquidity constraints.
• Suppliers may face challenges with timely payments and ongoing relationships due to the company's liquidity constraints and the CCAA filing.
• Management has undergone significant changes in leadership roles and responsibilities, including the resignation of former CEO Adesh Vora, indicating instability at the executive level.

Next Steps

• Implement a viable restructuring plan through the CCAA process for SRx Canada.
• Seek additional capital through equity and/or debt offerings.
• Continue discussions with existing and potential lenders to restructure or refinance outstanding debt and obtain covenant waivers.
• Implement cost control measures and operational efficiencies to reduce cash burn.
• Scale higher-margin service lines and expand the commercial footprint to increase revenue.
• Evaluate the monetization or divestiture of non-core assets to improve liquidity.
• Actively evaluate strategic alternatives for the U.S. pet food business (Halo), including potential restructuring, divestiture, or wind-down.
• Strengthen internal control environment by enhancing documentation, improving oversight of technical accounting, formalizing internal control processes, and upgrading system controls.
• Monitor and adjust remediation plans for identified material weaknesses in internal controls.

Key Dates

Recommendation

The company is in severe financial distress, evidenced by a substantial increase in net loss, a significant decline in net sales, and a negative Adjusted EBITDA. The 'going concern' warning, non-compliance with debt covenants, and the subsequent CCAA filing for its core Canadian operations indicate a high risk of insolvency or significant restructuring that could severely impact shareholder value. Identified material weaknesses in internal controls, including management override, further erode confidence. While recent capital raises provide some short-term liquidity, they are insufficient to offset the fundamental operational and financial challenges. The U.S. pet food segment also faces significant liquidity issues. Given these factors, a seasoned investor would likely recommend a strong sell to minimize further losses.

Keywords

Healthcare services, Pharmacy operations, Specialty medications, Pet wellness, SEC filing, Financial results, Reverse merger, Going concern, Creditor protection, CCAA, Liquidity, Debt covenants, Internal controls, Halo pet food, Canada, United States, SRx Health Solutions, Better Choice Company